Hikma Pharmaceuticals Plc Stock Performance
| HKMPF Stock | USD 24.47 1.91 8.47% |
The company retains a Market Volatility (i.e., Beta) of 0.095, which attests to not very significant fluctuations relative to the market. As returns on the market increase, Hikma Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Hikma Pharmaceuticals is expected to be smaller as well. At this point, Hikma Pharmaceuticals PLC has a negative expected return of -0.0836%. Please make sure to check out Hikma Pharmaceuticals' total risk alpha, as well as the relationship between the daily balance of power and price action indicator , to decide if Hikma Pharmaceuticals PLC performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Hikma Pharmaceuticals PLC has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable basic indicators, Hikma Pharmaceuticals is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 323 M | |
| Total Cashflows From Investing Activities | -238 M |
Hikma |
Hikma Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 2,596 in Hikma Pharmaceuticals PLC on August 30, 2024 and sell it today you would lose (149.00) from holding Hikma Pharmaceuticals PLC or give up 5.74% of portfolio value over 90 days. Hikma Pharmaceuticals PLC is currently producing negative expected returns and takes up 1.4501% volatility of returns over 90 trading days. Put another way, 12% of traded pink sheets are less volatile than Hikma, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Hikma Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Hikma Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Hikma Pharmaceuticals PLC, and traders can use it to determine the average amount a Hikma Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0576
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | HKMPF |
Estimated Market Risk
| 1.45 actual daily | 12 88% of assets are more volatile |
Expected Return
| -0.08 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.06 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Hikma Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Hikma Pharmaceuticals by adding Hikma Pharmaceuticals to a well-diversified portfolio.
Hikma Pharmaceuticals Fundamentals Growth
Hikma Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Hikma Pharmaceuticals, and Hikma Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Hikma Pink Sheet performance.
| Return On Equity | 0.15 | |||
| Return On Asset | 0.077 | |||
| Profit Margin | 0.14 % | |||
| Operating Margin | 0.22 % | |||
| Current Valuation | 5.26 B | |||
| Shares Outstanding | 220.26 M | |||
| Price To Earning | 7.89 X | |||
| Price To Book | 1.84 X | |||
| Price To Sales | 1.63 X | |||
| Revenue | 2.55 B | |||
| EBITDA | 758 M | |||
| Cash And Equivalents | 393 M | |||
| Cash Per Share | 1.78 X | |||
| Total Debt | 651 M | |||
| Debt To Equity | 0.71 % | |||
| Book Value Per Share | 9.89 X | |||
| Cash Flow From Operations | 638 M | |||
| Earnings Per Share | 1.50 X | |||
| Total Asset | 4.37 B | |||
| Retained Earnings | 1.16 B | |||
| Current Asset | 1.36 B | |||
| Current Liabilities | 592 M | |||
About Hikma Pharmaceuticals Performance
By analyzing Hikma Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Hikma Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Hikma Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Hikma Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company was founded in 1978 and is based in London, the United Kingdom. Hikma Pharmaceutical operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 8700 people.Things to note about Hikma Pharmaceuticals PLC performance evaluation
Checking the ongoing alerts about Hikma Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Hikma Pharmaceuticals PLC help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Hikma Pharmaceuticals generated a negative expected return over the last 90 days | |
| About 30.0% of the company shares are held by company insiders |
- Analyzing Hikma Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Hikma Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Hikma Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Hikma Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Hikma Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Hikma Pharmaceuticals' pink sheet. These opinions can provide insight into Hikma Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Hikma Pink Sheet analysis
When running Hikma Pharmaceuticals' price analysis, check to measure Hikma Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hikma Pharmaceuticals is operating at the current time. Most of Hikma Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Hikma Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hikma Pharmaceuticals' price. Additionally, you may evaluate how the addition of Hikma Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing |